跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

MSD INTERNATIONAL GMBH (PUERTO RICO BRANCH) LLC

首页临床试验发起方与机构MSD INTERNATIONAL GMBH (PUERTO RICO BRANCH) LLC

MSD INTERNATIONAL GMBH (PUERTO RICO BRANCH) LLC

Pridco Indus Park Sr 183, Las Piedras, Puerto Rico, 美国

别名:

merck

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

28

2 进行中

药物批准

32

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

3 期

9

32.1%

2 期

8

28.6%

4 期

4

14.3%

试验状态分布

已完成

23

82.1%

尚未招募

2

7.1%

招募中

1

3.6%

撤回

2

7.1%

相关临床试验

该机构主办的试验（28）

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

20 名受试者

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (MS200647-0037)

34 名受试者

A multicentre, open label, Phase I trial of the MEK inhibitor MSC1936369B given orally to Subjects with Solid Tumours

50 名受试者

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non*small-cell lung cancer

An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)

96 名受试者

A Phase II, two arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)

A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial

A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX in Subjects >=60 Years of Age

750 名受试者

药物批准

按机构分类的批准

EMC

Electronic Medicines Compendium

30

药物批准

PHILIPPINES

Philippines FDA

2

药物批准

近期批准

Cladribine Merck 10 mg tablets

Glucophage 850 mg film coated tablets

Glucophage SR 750 mg prolonged release tablets

Cardicor 5mg Film Coated Tablets

Ovitrelle 250 micrograms/0.5 ml prefilled syringe

TEPMETKO 225 mg film-coated tablets

Bavencio 20 mg/mL concentrate for solution for infusion

Cardicor 2.5mg Film Coated Tablets

GONAL-f 75 IU (5.5 micrograms)

Glucophage 500 mg film coated tablets

资讯

Merck's Phase 2 KeyVibe-002 Trial Shows Mixed Results for Novel TIGIT Inhibitor Combination in Advanced NSCLC

Merck's Phase 2 KeyVibe-002 trial evaluated vibostolimab/pembrolizumab combination with or without docetaxel in previously treated metastatic non-small cell lung cancer patients. While the combination with docetaxel showed a modest improvement in progression-free survival, the results did not reach statistical significance. The safety profile was consistent with previous studies, with no new safety signals identified.

本页目录

概览
相关临床试验28
药物批准32
资讯1

返回机构列表